2025-No. 3394 Supply of Drugs for Medical Use: Levetiracetam, Levodop + Bensserasid, Pregabalin

RussiaTenders notice for 2025-No. 3394 Supply of Drugs for Medical Use: Levetiracetam, Levodop + Bensserasid, Pregabalin. The reference ID of the tender is 113930396 and it is closing on 06 Feb 2025.

100% Secure Payments

Tender Details

  • Country: Russia
  • Summary: 2025-No. 3394 Supply of Drugs for Medical Use: Levetiracetam, Levodop + Bensserasid, Pregabalin
  • RUT Ref No: 113930396
  • Deadline: 06 Feb 2025
  • Competition: ICB
  • Financier: Self Financed
  • Purchaser Ownership: Public
  • Tender Value: 4152752.80
  • Notice Type: Tender
  • Document Ref. No.: 0851200000625000133
  • Purchaser's Detail :
  • Purchaser : STATE STATE INSTITUTION OF THE NOVOSIBIRSK REGION "OFFICE OF THE CONTRACT SYSTEM
    630005, Novosibirsk Region, Novosibirsk, Frunze St., Zd. 88, Office 401
    F.I.O:- Popova M.M.
    Contact phone number:- 8-383-2387272-6037
    fax:- Information is missing
    Email :uksis@zakaznso.ru

  • Description :
  • 2025-No. 3394 Supply of drugs for medical use: levetiracetam, levodop + Bensserasid, Pregabalin
  • Documents :
  •  Tender Notice

If you are registered member, kindly login to view full details of this tender notice:

CLICK HERE TO LOGIN
RussiaTenders Features

RussiaTenders Features

Fresh and verified Tenders from Russia. Find, search and filter Tenders/Call for bids/RFIs/RFPs/RFQs/Auctions published by the government, public sector undertakings (PSUs) and private entities.

  • 1,000+ Tenders
  • Verified Tenders Only
  • Accurate Tender Information
  • New Tenders Every Day
  • Consultants for RFI/RFP/RFQ
  • Search, sort, and filter Tenders
  • Customer Support
  • Publish your Tenders
  • Consulting Services
  • Export data to Excel or CRM

Get A Call From Tender Experts

Fill out the form below and you will receive a call from us within 24 hours.

Thank You for Contacting ZimbabweTenders !!
Email Id is already exist !!
Invalid Captcha !

Get FREE SAMPLE TENDERS from Russia in your email inbox.

  Chat with us